SLC2A1, solute carrier family 2 member 1, 6513

N. diseases: 687; N. variants: 76
Disease: melanoma ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0025202
Disease: melanoma
melanoma 		0.100 GeneticVariation disease BEFREE While under normoxic conditions the expression of glycolysis-related genes showed no correlation with origin or BRAF mutation status, GLUT1 expression was significantly elevated in metastatic and BRAF-V600E mutated melanoma cell lines under hypoxic conditions. 31791701 2020
CUI: C0025202
Disease: melanoma
melanoma 		0.100 AlteredExpression disease BEFREE Of melanoma cases, 85.3% expressed either GLUT1 or GLUT3 or both, 39.4% of melanoma cases coexpressed GLUT1 and GLUT3, 17.4% of melanoma cases only expressed GLUT1, 28.4% of melanoma cases only expressed GLUT3, and 14.7% of melanoma cases were negative for both markers. 31135601 2019
CUI: C0025202
Disease: melanoma
melanoma 		0.100 Biomarker disease BEFREE <b>Conclusions:</b> We concluded that ITCH may downregulate GLUT1 and suppresses glucose uptake in melanoma to inhibit cancer cell proliferation. 31403357 2019
CUI: C0025202
Disease: melanoma
melanoma 		0.100 Biomarker disease BEFREE The number of positive cases and the H-score of Glut-1 increased where there was a higher Breslow thickness (p < 0.00001) when comparing pT1- pT4 MM groups. 29128957 2019
CUI: C0025202
Disease: melanoma
melanoma 		0.100 AlteredExpression disease BEFREE Increased GLUT1 (Glucose Transporter Type 1) expression has been demonstrated earlier in malignant melanomas. 29929176 2018
CUI: C0025202
Disease: melanoma
melanoma 		0.100 GeneticVariation disease BEFREE Tissue samples from normal skin, melanocytic naevi and melanoma were subjected to immunohistochemistry for two TT-Cs (Cav3.1, Cav3.2); markers of proliferation (Ki67), the cell cycle (cyclin D1), hypoxia (Glut1), vascularization (CD31) and autophagy (LC3); BRAF V600E mutation (VE1) and phosphatase and tensin homologue (PTEN). 27718503 2017
CUI: C0025202
Disease: melanoma
melanoma 		0.100 Biomarker disease BEFREE Furthermore, silencing of GLUT1 in the melanoma cells resulted in the increased expression of WNT5A and the decreased ability of invasion and proliferation in the melanoma cells. 26934938 2016
CUI: C0025202
Disease: melanoma
melanoma 		0.100 Biomarker disease BEFREE In addition, CD147 and GLUT-1 were co-localized in the cytoplasm of human melanoma A375 cells. 27556188 2016
CUI: C0025202
Disease: melanoma
melanoma 		0.100 Biomarker disease BEFREE In conclusion, we have determined that the l-cysteine/CSE/H2 S pathway is involved in melanoma progression. 25205294 2015
CUI: C0025202
Disease: melanoma
melanoma 		0.100 Biomarker disease BEFREE Treatment of four different human melanoma cell lines with a pharmacological GLUT1 inhibitor caused a dose-dependent reduction of proliferation, apoptosis resistance, migratory activity and MMP2 expression. 26293674 2015
CUI: C0025202
Disease: melanoma
melanoma 		0.100 Biomarker disease BEFREE However, the effects on overall or disease free survival in melanoma patients were modest or absent for GLUT-1 or for HIF-1α, respectively. 24997364 2014
CUI: C0025202
Disease: melanoma
melanoma 		0.100 AlteredExpression disease LHGDN Our results suggest that glucose transporter Glut-1 expression can significantly discriminate between human malignant melanoma and benign melanocytic nevi, and support the idea that additional mechanisms other than Glut-1 may contribute to glucose uptake in melanomas. 18764953 2008
CUI: C0025202
Disease: melanoma
melanoma 		0.100 Biomarker disease BEFREE Glut1 reactivity was absent in the melanomas and seborrheic keratoses. 9344196 1997